|
Primary Tumor Resection for M1a Stage Lung Cancer
RECRUITINGSponsored by Fudan University
Actively Recruiting
SponsorFudan University
Started2024-04-01
Est. completion2025-12
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06547710
Summary
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1023. This study aims to explore the safety and efficacy of primary lesion resection in the treatment of M1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the OS and quality of life of the corresponding patients.
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures; 2. Aged 18-80 years (including critical values) when signing the informed consent form; 3. ECOG score 0 or 1; 4. No previous lung cancer surgery; 5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer; 6. Occult pleural metastasis found during surgery; 7. Preoperative lymph node staging is cN0; 8. First-time treatment and no radiotherapy or chemotherapy. Exclusion Criteria: 1. The lesion cannot be completely removed surgically; 2. Cytological or histological pathology confirms other lung malignancies other than lung cancer; 3. Patients who have undergone lung cancer surgery before; 4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.
Conditions4
CancerLung CancerLung Cancer MetastaticSurgical Resection
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorFudan University
Started2024-04-01
Est. completion2025-12
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06547710